There are reports of neurological adverse events associated with immune checkpoint inhibitors, including pembrolizumab. These events may include autoimmune encephalitis and other neurotoxicities, with some cases presenting with rare conditions such as autoimmune pancerebellitis. The relationship between these inhibitors and neurological toxicity is being studied and documented in various case reports and reviews.